Exelixis (EXEL) is down -15.7%, or -$6.97 to $37.42.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target lowered to $46 from $48 at Morgan Stanley
- Exelixis price target lowered to $49 from $56 at Truist
- Exelixis price target lowered to $45 from $50 at RBC Capital
- Exelixis’s Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations
- Exelixis Stock Performance: Hold Rating Amid Earnings Miss and Strategic Concerns